MACERICH CO (MAC): what the price assumes

In the published model solve dated 2026-Q2, anchored at $26.32, MACERICH CO (MAC) is priced for today's economics sustained for ~10.7 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/MAC

Headline

FieldValue
TickerMAC
CompanyMACERICH CO
Current price$26.32/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisreit
Top-of-range FFO growth must hold for10.7y
Price-to-FFO22.1x
FFO yield4.5%

Solve inputs: computed at a 13.4% cost of equity; growth searched up to the 15% ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~9%/yr; the models below use their own rates.

How unusual the bet is: extreme

ReferenceValue
vs own history+0.31σ
cohort percentile (of 105 peers)87
sustained it ~10 years at this level53%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.79x3expensive
Earnings0
Relative1.52x3expensive
Growth4.92x2expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$17.051.54xnoFCF base $0.3B, growth 6% (input: historical growth), terminal g 4.0%, WACC 7.0%, 6yr projection
DCF Exit MultipleGrowth$18.271.44xnoExit EV/EBITDA: 29.9x / 31.9x / 33.9x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$28.350.93xyesP/E 35x (static sector reference · 2026-04), scenarios: 29.2x / 35.0x / 40.8x (bear / base = reference held flat / bull), EV/EBITDA 23.58x
Simple DDMGrowth$4.196.28xyesDPS $0.76, g=-7.5% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$7.403.56xyesStage 1: -10% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$9.452.79xyesReference only (book value floor): BV/sh $9.45, ROE negative
Two-Stage Excess ReturnAsset$8.503.10xyesReference only (book value with convergence): BV/sh $9.45, ROE converges to ke
Discounted Future Market CapGrowth$14.351.83xnoRev $1.0B, growth 6% (input: historical growth; tapered), Terminal P/S: 5.6x / 6.7x / 7.9x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$15.971.65xyes√(22.5 × FFO/share $1.20 × BVPS $9.45) — Graham's conservative floor
EV/EBITDA RelativeRelative$9.732.71xyesEBITDA $0.36B × sector EV/EBITDA 20.0x
FCF YieldEarnings$0.012632.00xyesFCF $310.5M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.012632.00xyesSBC-adj FCF $0.29B (FCF $0.31B − SBC $0.02B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$1.0126.06xyesFFO/share $1.20 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAssetno
P/Sales SectorRelative$23.401.12xnoRevenue $1.01B × sector P/S 6.0x
PEG Fair ValueRelativeno
Earnings YieldEarnings$12.972.03xnoFFO/share $1.20 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative$17.271.52xyesFFO/share $1.20 × 14.3x P/FFO (route cohort median, n=85); FFO $0.31B (FFO incl. D&A + impairments, FY2025, companyfacts), shares 258M
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Funds from operations (trailing)$310.6m
Share count CAGR (dilution)4.7%
Burning cashno

REIT basis: leverage is read against funds from operations (FFO), not depreciation-gutted operating income. The header's implied growth runs on ADJUSTED FFO — FFO minus recurring maintenance capex — so the header's multiple and this leverage ratio use bases that differ by that capex; neither substitutes for the other. Net debt could not be resolved from the corporate debt tags in the filings (REIT notes and mortgage debt are often tagged outside the corporate ladder), so the leverage ratio is withheld rather than rendered from incomplete tags. Interest expense is not separately reported in the cached statements, so fixed-charge coverage cannot be computed.

Bullet Takeaways

The balance sheet is the whole story here. Net debt to EBITDA has fallen from 8.76 times at the end of 2023 to 7.76 times by March 2026, with a stated target near 6.0 times, and management has completed roughly $1.3 billion of dispositions to get there.

Leasing is filling the malls. Q1 2026 FFO as adjusted of $0.34 per share beat consensus, 1.6 million square feet was signed, and a signed-not-open pipeline of $116 million in contracted revenue is set to open largely in the back half.

The price already prices the recovery. At $23.61 the asset-value and forward-growth frames both read the stock as expensive, and the embedded bet runs roughly ten years out, so the buyer is underwriting a long deleveraging arc with little room for error.

Bull Case

The balance sheet tells you where management's confidence actually sits, and at Macerich the deleveraging is real and measurable. Net debt to EBITDA has dropped from 8.76 times at year-end 2023 to 7.76 times as of March 31, 2026, a 1.5-turn improvement, with a stated target of roughly 6.0 times. The company has completed about $1.3 billion of dispositions and targets another $300 million to $400 million in 2026. The 10-K documents the refinancing machine behind this: the company "continues to actively address its near-term, non-recourse loan maturities, with eleven completed transactions since the beginning of 2024, totaling approximately $2.1 billion" (FY2025 10-K, accession 0000912242-26-000016). A management team that is selling assets and refinancing maturities on schedule is acting like a team that believes the equity is worth saving.

The operating engine underneath the debt is improving, not deteriorating. Q1 2026 FFO as adjusted came in at $0.34 per diluted share, beating consensus by nearly 10%, with reported occupancy at 93.4% and leased occupancy up 80 basis points year over year. Leasing momentum was strong: 1.6 million square feet signed in the quarter, including 700,000 square feet of new deals, and a signed-not-open pipeline carrying $116 million of cumulative contracted revenue. That pipeline is the bull's clearest near-term lever, because the 10-K notes the company expects to "experience organic growth in EBITDA as tenants in its lease pipeline open for business" (FY2025 10-K, accession 0000912242-26-000016). Revenue already signed, not yet open, is the most visible form of forward growth a mall owner can point to.

The structure of the debt limits the downside. The 10-K confirms that "all of the Company's mortgage notes payable are secured by the properties on which they are placed and are non-recourse to the Company" (FY2025 10-K, accession 0000912242-26-000016), which means a single troubled asset can be handed back to its lender without sinking the whole enterprise. Pair non-recourse debt with a Class A mall focus, a 2028 plan targeting 88% to 89% occupancy and low-to-mid 6 times leverage, and guidance for at least 3% go-forward NOI growth in 2026, and the bull case is a credible, self-funded recovery that the analyst price target has begun to follow upward.

Bear Case

The structural truth a Macerich holder would rather not face is plain: this is a leveraged owner of enclosed malls, a real-estate category in long secular decline, and the price already assumes the turnaround works. The cheap-because-of-what-is-deteriorating risk is acute here. Even after meaningful progress, net debt to EBITDA is still 7.76 times, a level most equity investors would call distressed in any other property type, and net debt of roughly $4.7 billion dwarfs trailing funds from operations near $311 million. The deleveraging that bulls celebrate is necessary precisely because the leverage was, and remains, dangerous.

Against the $23.61 price (June 27, 2026), the asset-based and forward-growth families both read the stock as expensive, and the blended X-ray figure lands near $9.45, far below the price. The priced-in characterization is extreme, with an implied bet stretching roughly ten years out, which is the model's way of saying the price requires the Path Forward Plan to execute almost perfectly over a long horizon. The 10-K itself cautions that the steps "the Company has or will undertake while implementing the Path Forward Plan may vary and evolve" (FY2025 10-K, accession 0000912242-26-000016), an honest acknowledgment that the plan is a path, not a guarantee.

The refinancing dependency is the quiet fragility. The same 10-K that touts completed refinancings also discloses that the company "expects all loan maturities during the next twelve months will be refinanced" (FY2025 10-K, accession 0000912242-26-000016), which is fine in an accommodative market and a problem if rates rise or lenders retreat from retail real estate. Non-recourse debt protects the parent from any single property, but it also means handing keys back shrinks the asset base and the FFO that supports the equity. The dividend yield sits near 2.9%, below peer averages, so income offers little cushion while the deleveraging plays out. At this price the buyer is not getting cheap mall real estate; the buyer is paying ahead of a ten-year recovery in a declining category carried on still-high leverage.

Valuation

Macerich is valued on funds from operations, and the price sits well ahead of where most methods land. Against the $23.61 quote, the earnings-power family supports the price, but the asset-based and forward-growth families both flag it as expensive, and the blended X-ray figure across five methods lands near $9.45. That is a large gap, and it reflects the central tension: the market is paying for a recovery that the conservative, present-tense methods do not yet see in the numbers. The priced-in characterization is extreme, with an implied duration of roughly ten years, meaning the price embeds a long execution runway rather than current cash flow.

The leverage is the dominant valuation input and it cannot be rendered cleanly. Net debt of about $4.7 billion against trailing FFO near $311 million is the headline, but because interest expense is not separately broken out in the cached statements, fixed-charge coverage cannot be computed, and leverage is read against FFO rather than a precise ratio. On an EBITDA basis the company reports 7.76 times net debt to EBITDA as of March 2026, improved from 8.76 times but still high. The refinancing cadence documented in the 10-K, eleven transactions totaling roughly $2.1 billion since 2024 (FY2025 10-K, accession 0000912242-26-000016), is what keeps the capital structure standing.

The honest read is that this is a turnaround equity, not a value-with-a-floor REIT. The earnings-power support says the in-place cash flow has stabilized; the asset and growth methods say you are paying for improvement not yet delivered. The signed-not-open pipeline of $116 million is the strongest argument that forward FFO rises from here, and the 2028 targets of 88% to 89% occupancy and low-to-mid 6 times leverage are the milestones that would justify the price. The buyer is underwriting that deleveraging plus pipeline opening lifts FFO faster than the secular drag on malls erodes it, over a long horizon, with a thin dividend yield as the only interim payment.

Catalysts

Q1 2026 results (reported May 2026) advanced the turnaround narrative. FFO as adjusted of $0.34 per diluted share matched the year-ago level and beat the Zacks consensus by nearly 10%, with reported occupancy at 93.4% and leased occupancy up 80 basis points year over year. Leasing was the standout: 1.6 million square feet signed including 700,000 square feet of new deals, and a signed-not-open pipeline of $116 million in cumulative contracted revenue. Guidance calls for at least 3% go-forward NOI growth in 2026, weighted to the back half as signed-not-open projects open, which makes the timing of those openings the key near-term catalyst.

The deleveraging milestones are the structural catalyst. Net debt to EBITDA fell to 7.76 times by March 31, 2026 from 8.76 times at year-end 2023, the company has completed roughly $1.3 billion of dispositions with another $300 million to $400 million targeted for 2026, and the Path Forward Plan targets low-to-mid 6 times leverage and 88% to 89% physical permanent occupancy by 2028. Each disposition, refinancing, and step-down in the leverage ratio is a discrete event the market can mark progress against, and the next twelve months of loan maturities the 10-K flags for refinancing are the watch items on the risk side.

Sentiment has begun to follow the execution. Analyst price targets have moved up modestly, from roughly $21.63 to $23.13, as the Street responds to the balance-sheet progress and portfolio simplification, with a mix of optimism on execution and ongoing caution on valuation and long-term earnings power. The quarterly dividend of $0.17 per share, a roughly 2.9% yield, is the steady but modest interim return. The catalysts that would re-rate the stock are continued occupancy gains, the back-half opening of the signed-not-open pipeline, and a clear line of sight to the 6 times leverage target.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive MAC report on boothcheck